Gilead seeks approval for first-ever oral Hepatitis C drug Seattle Post Intelligencer (blog) Gilead is also taking heat internationally for its tentative plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $2,000, according to an interview with an Indian pharmaceutical executive in the Hindu ... |
